Human alpha thrombin, highly active



Order
Quantity
Price
Status
2x 100 U 200 € available


Documents
Art. No. T056
Synonym Coagulation factor IIa, α Thrombin
Molecular Weight 37 kDa
Source (Pro)thrombin from tested human plasma
Purity > 95% (visually by SDS-PAGE)
Specific Activity >3,000 NIH units/mg
Appearance white lyophilized solid
Reagents lyophilized from 50 mM sodium citrate / 0.2 M NaCl / 0.1% PEG-8.000 pH 6.5.
Reconstitution add 0.01 ml of water. After reconstitution the solution should be stored at -20°C in working aliquots.
Avoid repeated freezing and thawing.
Application coagulation research, medical research, protein-structure, sequence analysis, and biochemical research.
Storage store at 4°C.
Delivery at ambient temperature is possible
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy